Financial Data and Key Metrics Changes - Aflac reported Q4 2025 net earnings per diluted share of $2.64 and adjusted earnings per diluted share of $1.57, with full-year net earnings per diluted share at $6.82 and adjusted earnings at $7.49 [5] - Adjusted earnings per diluted share increased 0.6% year-over-year for Q4 2025, while adjusted book value per share rose 0.5% [14] - The adjusted return on equity (ROE) was 11.7%, and 14.5% excluding foreign currency remeasurement [14] Business Line Data and Key Metrics Changes - Aflac Japan's sales increased by 15.7% in Q4 and 16% for the full year 2025, driven by the launch of the Moraito cancer insurance product [6][7] - Aflac U.S. generated nearly $1.6 billion in new sales for 2025, with over one-third coming from Q4 [8] - Premium persistency in Aflac Japan remained strong at 93.1%, while Aflac U.S. reported a persistency of 79.2% [9][10] Market Data and Key Metrics Changes - Aflac Japan's net earned premiums in yen terms declined by 1.9% for Q4 2025, while underlying earned premiums decreased by 1.2% [14][15] - In the U.S., net earned premiums increased by 4%, but the total benefit ratio rose to 48.6%, driven by higher claims activity [17] Company Strategy and Development Direction - Aflac continues to emphasize third sector protection and has introduced innovative products to meet changing customer needs [7][8] - The company aims to maintain strong premium persistency while offsetting the impact of reinsurance and policies reaching paid-up status [7] - Aflac plans to enhance its capital deployment strategy, including a 5.2% increase in dividends for Q1 2026 and a record $3.5 billion in share repurchases for 2025 [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial strength and ability to navigate increasing out-of-pocket medical expenses faced by consumers [10] - The outlook for 2026 includes expectations for underlying earned premiums in Japan to decline by 1%-2% and net earned premium growth in the U.S. to be in the lower end of the 3%-6% range [25] Other Important Information - Aflac's capital position remains strong, with an SMR above 970% and an estimated regulatory ESR of 253% [22][23] - The company has enhanced liquidity and capital flexibility by creating off-balance sheet pre-capitalized trusts [21] Q&A Session Summary Question: Concerns about surrender levels in Japan due to rising yields - Management acknowledged the potential for increased surrenders but noted that they have not yet experienced significant changes [30] Question: Impact of ESR on M&A or capital deployment - Management confirmed that while capital is available for M&A, finding suitable operational and strategic targets remains challenging [33] Question: Lower benefit ratio guidance in Japan - Management explained that the lower benefit ratio is influenced by updated actuarial assumptions and new product introductions [36][38] Question: Group versus non-group sales performance - Management reported strong growth in group sales, particularly in network dental and vision products, while traditional voluntary benefits have been flat [72] Question: Future premium growth in Japan - Management indicated that strong persistency is limiting premium growth, with expectations for a positive turn in the future [78]